Castle Biosciences, Inc.
DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging
SDPA analysis demonstrates DecisionDx-Melanoma can identify higher-risk patients within a traditionally low-risk population with thin melanomas…
